View Future Growth1CM 과거 순이익 실적과거 기준 점검 4/61CM은 연평균 68%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.8% 증가했습니다. 매출은 연평균 51.5%의 비율로 증가했습니다. 1CM의 자기자본이익률은 14%이고 순이익률은 6.3%입니다.핵심 정보68.03%순이익 성장률69.36%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률51.52%자기자본이익률13.97%순이익률6.30%최근 순이익 업데이트31 May 2026최근 과거 실적 업데이트Reported Earnings • Aug 04Third quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0 in 3Q 2025)Third quarter 2026 results: EPS: CA$0.004 (up from CA$0 in 3Q 2025). Revenue: CA$18.7m (up 2.2% from 3Q 2025). Net income: CA$475.3k (up CA$430.1k from 3Q 2025). Profit margin: 2.5% (up from 0.2% in 3Q 2025).Reported Earnings • Jan 29First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.012 loss per share (down from CA$0.011 loss in 1Q 2021). Revenue: CA$228.1k (up 313% from 1Q 2021). Net loss: CA$991.0k (loss widened 10% from 1Q 2021). Revenue was in line with analyst estimates.모든 업데이트 보기Recent updatesReported Earnings • Aug 04Third quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0 in 3Q 2025)Third quarter 2026 results: EPS: CA$0.004 (up from CA$0 in 3Q 2025). Revenue: CA$18.7m (up 2.2% from 3Q 2025). Net income: CA$475.3k (up CA$430.1k from 3Q 2025). Profit margin: 2.5% (up from 0.2% in 3Q 2025).New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.28m (US$8.27m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (47% average weekly change). Market cap is less than US$10m (€7.28m market cap, or US$8.27m). Minor Risk Large one-off items impacting financial results.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Tanvi Bhandari was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jan 081CM Inc. Announces Chief Financial Officer Changes, Effective January 7, 20261CM Inc. announced that its board of directors has appointed Antony Pramoth as Chief Financial Officer of the company. Mr. Pramoth succeeds Harshil Chovatiya, who has served as the Company's Chief Financial Officer since February 24, 2023, effective January 7, 2026. Mr. Pramoth has been with the company since October 2023. The company is promoted Mr. Pramoth to the role of CFO.공고 • Apr 231CM Inc., Annual General Meeting, Jun 16, 20251CM Inc., Annual General Meeting, Jun 16, 2025. Location: ontario, toronto Canada공고 • Sep 261Cm Inc. Expands its Operations Adding Tobacco, CPG, Private Label Products1CM Inc. announce the addition of Tobacco, Vape & Consumer Packaged Goods products to its retail portfolio. 1CM has begun retailing cigarettes and vape products as an authorized retailer of Imperial Tobacco Canada Ltd. A wholly owned subsidiary of British American Tobacco and Rothmans Benson & Hedges Inc. A wholly owned subsidiary of Altria (formerly Philip Morris International). These products are purchased directly from the manufacturers. 1CM has further begun retailing complimentary CPG products from Pepsi, Frito-Lay, Parmalat & Canada Bread. The products are distributed to the company from Arctic Beverages. 1CM has also begun producing its private label Vodka and Vodka Iced Tea. Under the brand "EPIC MILFF". These products are manufactured in collaboration with Minhas Sask Ventures Inc. This strategic horizontal expansion marks a significant milestone for the 1CM as it now extends its operations to Tobacco, CPG and Private Label products. 1CM will continue to leverage its technology to warehouse, mine and obtain insights from the valuable data obtained from its retail customers of Cannabis, Liquor, Tobacco, & CPG products. This data will allow the company to determine channel complementarity and provide unique cross-channel marketing opportunities and experiences to the age-gated 1CM customers. In industries like Tobacco and Cannabis with strict regulations around marketing, this provides an invaluable resource to 1CM and the tobacco industry as they will have a compliant marketing opportunity, supported by high quality data on purchasing patterns across multiple channels. 1CM is building a reputation in the liquor retail industry for its commitment to exceptional customer service, and value. These new product offerings will improve the customer experience and increase revenues.공고 • Aug 011CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million.1CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million on December 1, 2022.1CM Inc. (CNSX:EPIC) completed the acquisition of Fresh Cannabis Co. Inc. from Cost Cannabis Inc. on December 1, 2022.Board Change • Sep 15High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Lucas Leone is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 29First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.012 loss per share (down from CA$0.011 loss in 1Q 2021). Revenue: CA$228.1k (up 313% from 1Q 2021). Net loss: CA$991.0k (loss widened 10% from 1Q 2021). Revenue was in line with analyst estimates.Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Is New 90 Day High Low • Mar 06New 90-day high: €0.37The company is up 215% from its price of €0.12 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Is New 90 Day High Low • Feb 11New 90-day high: €0.35The company is up 249% from its price of €0.099 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 22New 90-day high: €0.22The company is up 136% from its price of €0.095 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period.매출 및 비용 세부 내역1CM가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:IQ70 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 May 2675513028 Feb 2675413030 Nov 2575113031 Aug 2573012031 May 2570210028 Feb 256729030 Nov 246219031 Aug 245718031 May 2452-18029 Feb 2446-18030 Nov 2340-27031 Aug 2335-17031 May 2324-27028 Feb 2315-36030 Nov 228-34031 Aug 221-53031 May 221-54028 Feb 221-55030 Nov 211-54031 Aug 210-54031 May 210-42028 Feb 210-31030 Nov 200-31031 Aug 200-31031 May 200-281029 Feb 200-281030 Nov 190-281031 Aug 190-291031 May 190-75028 Feb 190-86030 Nov 180-76031 Aug 180-66031 May 180-22028 Feb 18000030 Nov 17000031 Aug 17000031 May 17000028 Feb 17000030 Nov 16000031 Aug 16000031 May 160-10029 Feb 160-10030 Nov 150-100양질의 수익: IQ70는 CA$4.1M 규모의 큰 일회성 이익이 있어 31st May, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: IQ70의 현재 순 이익률 (6.3%)은 지난해 (2.5%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: IQ70는 지난 5년 동안 흑자전환하며 연평균 68%의 수익 성장을 기록했습니다.성장 가속화: 지난 1년간 IQ70 의 수익 증가율(172.5%)은 연간 평균(68%)을 초과합니다.수익 대 산업: IQ70의 지난 1년 수익 증가율(172.5%)은 Pharmaceuticals 업계의 14.5%를 상회했습니다.자기자본이익률높은 ROE: IQ70의 자본 수익률(14%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/05 00:24종가2026/08/05 00:00수익2026/05/31연간 수익2025/08/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스1CM Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 04Third quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0 in 3Q 2025)Third quarter 2026 results: EPS: CA$0.004 (up from CA$0 in 3Q 2025). Revenue: CA$18.7m (up 2.2% from 3Q 2025). Net income: CA$475.3k (up CA$430.1k from 3Q 2025). Profit margin: 2.5% (up from 0.2% in 3Q 2025).
Reported Earnings • Jan 29First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.012 loss per share (down from CA$0.011 loss in 1Q 2021). Revenue: CA$228.1k (up 313% from 1Q 2021). Net loss: CA$991.0k (loss widened 10% from 1Q 2021). Revenue was in line with analyst estimates.
Reported Earnings • Aug 04Third quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0 in 3Q 2025)Third quarter 2026 results: EPS: CA$0.004 (up from CA$0 in 3Q 2025). Revenue: CA$18.7m (up 2.2% from 3Q 2025). Net income: CA$475.3k (up CA$430.1k from 3Q 2025). Profit margin: 2.5% (up from 0.2% in 3Q 2025).
New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.28m (US$8.27m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (47% average weekly change). Market cap is less than US$10m (€7.28m market cap, or US$8.27m). Minor Risk Large one-off items impacting financial results.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Tanvi Bhandari was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jan 081CM Inc. Announces Chief Financial Officer Changes, Effective January 7, 20261CM Inc. announced that its board of directors has appointed Antony Pramoth as Chief Financial Officer of the company. Mr. Pramoth succeeds Harshil Chovatiya, who has served as the Company's Chief Financial Officer since February 24, 2023, effective January 7, 2026. Mr. Pramoth has been with the company since October 2023. The company is promoted Mr. Pramoth to the role of CFO.
공고 • Apr 231CM Inc., Annual General Meeting, Jun 16, 20251CM Inc., Annual General Meeting, Jun 16, 2025. Location: ontario, toronto Canada
공고 • Sep 261Cm Inc. Expands its Operations Adding Tobacco, CPG, Private Label Products1CM Inc. announce the addition of Tobacco, Vape & Consumer Packaged Goods products to its retail portfolio. 1CM has begun retailing cigarettes and vape products as an authorized retailer of Imperial Tobacco Canada Ltd. A wholly owned subsidiary of British American Tobacco and Rothmans Benson & Hedges Inc. A wholly owned subsidiary of Altria (formerly Philip Morris International). These products are purchased directly from the manufacturers. 1CM has further begun retailing complimentary CPG products from Pepsi, Frito-Lay, Parmalat & Canada Bread. The products are distributed to the company from Arctic Beverages. 1CM has also begun producing its private label Vodka and Vodka Iced Tea. Under the brand "EPIC MILFF". These products are manufactured in collaboration with Minhas Sask Ventures Inc. This strategic horizontal expansion marks a significant milestone for the 1CM as it now extends its operations to Tobacco, CPG and Private Label products. 1CM will continue to leverage its technology to warehouse, mine and obtain insights from the valuable data obtained from its retail customers of Cannabis, Liquor, Tobacco, & CPG products. This data will allow the company to determine channel complementarity and provide unique cross-channel marketing opportunities and experiences to the age-gated 1CM customers. In industries like Tobacco and Cannabis with strict regulations around marketing, this provides an invaluable resource to 1CM and the tobacco industry as they will have a compliant marketing opportunity, supported by high quality data on purchasing patterns across multiple channels. 1CM is building a reputation in the liquor retail industry for its commitment to exceptional customer service, and value. These new product offerings will improve the customer experience and increase revenues.
공고 • Aug 011CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million.1CM Inc. (CNSX:EPIC) acquired Fresh Cannabis Co. Inc. from Cost Cannabis Inc. for CAD 0.38 million on December 1, 2022.1CM Inc. (CNSX:EPIC) completed the acquisition of Fresh Cannabis Co. Inc. from Cost Cannabis Inc. on December 1, 2022.
Board Change • Sep 15High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Lucas Leone is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 29First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: CA$0.012 loss per share (down from CA$0.011 loss in 1Q 2021). Revenue: CA$228.1k (up 313% from 1Q 2021). Net loss: CA$991.0k (loss widened 10% from 1Q 2021). Revenue was in line with analyst estimates.
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director R. Jarvis was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Is New 90 Day High Low • Mar 06New 90-day high: €0.37The company is up 215% from its price of €0.12 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Feb 11New 90-day high: €0.35The company is up 249% from its price of €0.099 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 22New 90-day high: €0.22The company is up 136% from its price of €0.095 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period.